As per Future Market Insights’ (FMIs’) latest revised industry analysis, the global Gamma Probe Devices Market was valued at over US$ 72.4 Mn in 2020, and is expected to exhibit a CAGR of close to 9.5% over the forecast period (2021-2031).
Gamma probe devices aid surgeons in identifying radio-labeled tissue prior to surgery for radio guided analysis, diagnosis, and operations. Surgeons frequently struggle to discover tissues within the human body, such as malignancies, parathyroid glands, and lymph nodes. As a result, appropriate use of a gamma probe device allows the medical expert to make a smaller incision even while locating the tissues of interest.
The rising number of thyroid and breast cancer disease patients and increasing preference for non-invasive procedures, owing to lesser hospital stay and cost effective solution also will drive the gamma probe devices market.
Most minimally invasive surgical procedures require gamma probe devices. Innovation in gamma probe devices and better patients outcomes in minimally invasive surgical procedures using gamma probe devices are also expected to boost the market growth.
The increasing preference for image guided procedures and recent advancements in gamma probe devices with low cost facility are also projected to favor the market growth over the forecast period.
For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10037
Gamma probe devices are increasingly being used in sentinel lymph node mapping in breast cancer and parathyroid surgery. As per WHO, 2.3 million women were diagnosed with cancer of breast while 685 thousand deaths happened due to the same reason in 2020.
As per Cancer research organization of the U.K, breast cancer is the fourth most common cause of cancer death in the UK, accounting about seven percent of all cancer deaths. Diseases such as breast cancer can be preventable if patients are diagnosed at an early stage.
However, till now, only few key players such as Hologic Inc., Danaher, BIODEX, and Southern Scientific Ltd. are actively involved in manufacturing of gamma probe devices, which will create huge opportunities for other small as well as big manufacturers to enter the gamma probe devices market.
Key Takeaways from Market Study
For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-gb-10037
“Increasing prevalence of breast cancer and surging awareness among the people about the benefits of gamma radiation in various treatment will boost the market over the forecast period” says an analyst at FMI.
The market for gamma probe devices is relatively consolidated. In this industry, there are several participants, with Hologic, LabLogic Group Holdings, and Danaher Corporation being the most prominent. These companies have strong product portfolios, product innovation, and business strategies that are cutting-edge.
These major market players have pursued a wide range of business approaches, including strategic partnerships with other medical device companies for product marketing and services, as well as collaboration with healthcare institutions for advanced technology research and development.
In August 2020, Hologic announced a collaboration with RadNet towards the development of artificial intelligence tools in breast health.
For Information On The Research Approach Used In The Report, Ask Analyst @ https://www.futuremarketinsights.com/askus/rep-gb-10037
In December 2019, Mammotome, a subdivision of Danahera Diagnostics, unveiled a new brand identity with an updated look and feel. Mammotome also began distribution of the TruCore TM II automatic core biopsy instrument in various regions.
• Comprehensive analysis on evolving purchase pattern across different geographies • Detailed insights of market segments and sub-segments for historical as well as forecast period • A competitive analysis of prominent players and emerging players in the keyword market • Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
For Read More Related Insights: https://acatpg.mn.co/posts/24303287?utm_source=manual https://hackmd.io/@6thpBmXwSImviVa9r9ComA/ryctqfPKc https://medium.com/@joshishital734/negative-pressure-wound-therapy-npwt-market-competitive-analysis-with-growth-forecast-till-2032-dbade0a5c485 https://community-specialists.tribe.so/post/negative-pressure-wound-therapy-npwt-market-growth-analysis-size-trends-eme–62a99da5317421613d96f206 https://speaknow.tribe.so/post/negative-pressure-wound-therapy-npwt-market-movements-by-trend-analysis-gro–62a99da2317421976d96f202 About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Unit No: 1602-006 Jumeirah Bay 2 Plot No: JLT-PH2-X2A Jumeirah Lakes Towers Dubai United Arab Emirates For Sales Enquiries: sales@futuremarketinsights.com For Media Enquiries: press@futuremarketinsights.com Website: https://www.futuremarketinsights.com LinkedIn| Twitter| Blogs
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2022 PHARMIWEB.COM LIMITED, rights reserved by the relevant holders.
You are leaving PharmiWeb.com
Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE
PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.
PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.
Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.
If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.